Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy

Severe asthma greatly affects patients’ quality of life. Major advances have occurred in the management of severe eosinophilic asthma the past few years due to the new targeted biological therapies. There are three anti-IL-5 mAbs, mepolizumab, reslizumab and benralizumab. Despite the different mecha...

Descripción completa

Detalles Bibliográficos
Autores principales: Bakakos, Agamemnon, Rovina, Nikoleta, Bakakos, Petros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069413/
https://www.ncbi.nlm.nih.gov/pubmed/33921360
http://dx.doi.org/10.3390/ijms22083969

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069413/
https://www.ncbi.nlm.nih.gov/pubmed/33921360
http://dx.doi.org/10.3390/ijms22083969

Ejemplares similares